<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugChangeHistoryOutput xmlns:ns2="local"><Change type="added"><Date>2012-01-28T04:34:54Z</Date><Reason id="2">Drug added</Reason></Change><Change type="added"><Date>2012-08-06T00:00:00Z</Date><Reason id="15">Technology added</Reason><DetailFormatted>&lt;Detail&gt;Biological therapeutic&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Biological therapeutic" id="761" name="technology"></Field></FieldsAdded></Change><Change type="updated"><Date>2013-09-15T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added [&lt;Link targetType="source" targetId="1457655"&gt;1457655&lt;/Link&gt;]&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1457655" type="updated"></SourceLink></CitationsAdded></Change><Change type="added"><Date>2013-11-28T00:00:00Z</Date><Reason id="15">Technology added</Reason><DetailFormatted>&lt;Detail&gt;Monoclonal antibody&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Monoclonal antibody" id="51" name="technology"></Field></FieldsAdded></Change><Change type="added"><Date>2013-11-28T00:00:00Z</Date><Reason id="15">Technology added</Reason><DetailFormatted>&lt;Detail&gt;Intravenous formulation&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Intravenous formulation" id="648" name="technology"></Field></FieldsAdded></Change><Change type="updated"><Date>2013-11-28T00:00:00Z</Date><Reason id="3">Drug name changed</Reason><DetailFormatted>&lt;Detail&gt;anti-LAG3 (cancer), Bristol-Myers Squibb to BMS-986016&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field newValue="BMS-986016" oldValue="anti-LAG3 (cancer), Bristol-Myers Squibb" name="drugNameDisplay"></Field></FieldsChanged></Change><Change type="updated"><Date>2013-11-28T00:00:00Z</Date><Reason id="10">Highest status change</Reason><DetailFormatted>&lt;Detail&gt;Discovery to Phase 1 Clinical&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field newValue="Phase 1 Clinical" newId="C1" oldValue="Discovery" oldId="DR" name="drugPhaseHighest"></Field></FieldsChanged></Change><Change type="UPDATED"><Date>2013-11-28T00:00:00Z</Date><Reason id="26">Development status: company/indication/territory trio status change</Reason><DetailFormatted>&lt;Detail&gt;Discovery to Phase 1 Clinical, US, &lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;, Cancer&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Cancer" id="651" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field newValue="Phase 1 Clinical" newId="C1" oldValue="Discovery" oldId="DR" name="drugPhaseHighest"></Field></FieldsChanged></Change><Change type="added"><Date>2013-11-28T00:00:00Z</Date><Reason id="4">Development profile section added</Reason><DetailFormatted>&lt;Detail&gt;Premarketing&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsAdded></Change><Change type="updated"><Date>2013-11-28T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added [&lt;Link targetType="source" targetId="1503948"&gt;1503948&lt;/Link&gt;]: Removed [&lt;Link targetType="source" targetId="1457655"&gt;1457655&lt;/Link&gt;]&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1503948" type="updated"></SourceLink></CitationsAdded><CitationsRemoved><SourceLink id="1457655" type="updated"></SourceLink></CitationsRemoved></Change><Change type="removed"><Date>2014-01-15T00:00:00Z</Date><Reason id="14">Other action removed</Reason><DetailFormatted>&lt;Detail&gt;Anticancer antibody&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Anticancer antibody" id="55684" name="action"></Field></FieldsRemoved></Change><Change type="added"><Date>2014-01-15T00:00:00Z</Date><Reason id="13">Other action added</Reason><DetailFormatted>&lt;Detail&gt;Anticancer monoclonal antibody&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Anticancer monoclonal antibody" id="55685" name="action"></Field></FieldsAdded></Change><Change type="removed"><Date>2014-01-15T00:00:00Z</Date><Reason id="16">Technology removed</Reason><DetailFormatted>&lt;Detail&gt;Antibody&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Antibody" id="1" name="technology"></Field></FieldsRemoved></Change><Change type="updated"><Date>2014-04-09T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added [&lt;Link targetType="source" targetId="1543968"&gt;1543968&lt;/Link&gt;]&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="1543968" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2014-04-09T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added [&lt;Link targetType="source" targetId="1543968"&gt;1543968&lt;/Link&gt;]&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1543968" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2014-07-24T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Japan, &lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;, Cancer&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Cancer" id="651" name="indication"></Field><Field value="Japan" id="JP" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2014-07-24T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Japan, &lt;Link targetType="company" targetId="18681"&gt;Ono Pharmaceutical Co Ltd&lt;/Link&gt;, Cancer&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Ono Pharmaceutical Co Ltd" id="18681" name="company"></Field><Field value="Cancer" id="651" name="indication"></Field><Field value="Japan" id="JP" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field></FieldsAdded></Change><Change type="added"><Date>2014-07-24T00:00:00Z</Date><Reason id="4">Development profile section added</Reason><DetailFormatted>&lt;Detail&gt;Additional Information&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field id="ADDITIONALINFO" name="drugDevProfileAdditionalInformation"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-05-07T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Cancer, 21-APR-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Cancer" id="651" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="21-APR-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="updated"><Date>2016-05-07T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; In April 2016, an open-label, randomized, parallel-assigned, phase II trial (NCT02750514; CA018-001) to evaluate the safety and efficacy of nivolumab in combination with dasatinib and BMS-986016 in patients (expected n = 685) with advanced cancer was planned in Canada. At that time, the trial was expected to complete in April 2020 [&lt;ulink linkID="1759748" linkType="Reference"&gt;1759748&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="1759748" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2016-05-23T00:00:00Z</Date><Reason id="10">Highest status change</Reason><FieldsChanged><Field newValue="Phase 2 Clinical" newId="C2" oldValue="Phase 1 Clinical" oldId="C1" name="drugPhaseHighest"></Field></FieldsChanged></Change><Change type="UPDATED"><Date>2016-05-23T00:00:00Z</Date><Reason id="26">Development status: company/indication/territory trio status change</Reason><FieldsChanged><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Cancer" id="651" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field newValue="Phase 2 Clinical" newId="C2" oldValue="Phase 1 Clinical" oldId="C1" name="drugPhaseHighest"></Field><Field value="12-MAY-16" name="devStatusDate"></Field></FieldsChanged></Change><Change type="updated"><Date>2016-05-23T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1759748" type="updated"></SourceLink></CitationsAdded><CitationsRemoved><SourceLink id="1503948" type="updated"></SourceLink><SourceLink id="1543968" type="updated"></SourceLink></CitationsRemoved></Change><Change type="Removed"><Date>2016-07-15T00:00:00Z</Date><Reason id="41">Clinical Trial Removed</Reason><DetailFormatted>&lt;Detail&gt;A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer, Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer" id="259316" name="trialTitle"></Field><Field value="Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors" id="158833" name="trialTitle"></Field></FieldsRemoved></Change><Change type="Removed"><Date>2016-07-27T00:00:00Z</Date><Reason id="41">Clinical Trial Removed</Reason><DetailFormatted>&lt;Detail&gt;Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematological Malignancies&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematological Malignancies" id="173219" name="trialTitle"></Field></FieldsRemoved></Change><Change type="Removed"><Date>2016-08-31T00:00:00Z</Date><Reason id="41">Clinical Trial Removed</Reason><DetailFormatted>&lt;Detail&gt;Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma" id="251405" name="trialTitle"></Field></FieldsRemoved></Change><Change type="ADDED"><Date>2016-10-24T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stomach tumor, 14-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stomach tumor" id="127" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="14-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-10-24T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Israel, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stomach tumor, 14-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stomach tumor" id="127" name="indication"></Field><Field value="Israel" id="IL" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="14-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-10-24T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Italy, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stomach tumor, 14-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stomach tumor" id="127" name="indication"></Field><Field value="Italy" id="IT" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="14-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-10-24T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stomach tumor, 14-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stomach tumor" id="127" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="14-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="removed"><Date>2016-10-24T00:00:00Z</Date><Reason id="6">Development profile section removed</Reason><DetailFormatted>&lt;Detail&gt;Additional Information&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field id="ADDITIONALINFO" name="drugDevProfileAdditionalInformation"></Field></FieldsRemoved></Change><Change type="updated"><Date>2016-10-24T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... CA018-003; 2016-002807-24; FRACTION-GC) to evaluate the safety and efficacy of BMS-986016 in combination with nivolumab and 	ipilimumab in patients (expected n = 910) with advanced gastric cancer was planned for November 2016 in the US, Canada, Israel and Italy. At that time, the trial was expected to complete in November 2021 [&lt;ulink linkID="1865820" linkType="Reference"&gt;1865820&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="1865820" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2016-10-24T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; Bristol-Myers Squibb (BMS) and licensee Ono Pharmaceuticals are developing BMS-986016, an anti-LAG3 mAb for the potential intravenous treatment of cancer including, gastric cancer [&lt;ulink linkID="1865820" linkType="Reference"&gt;1865820&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1865820" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Hematological neoplasm, 31-MAY-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Hematological neoplasm" id="2054" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="31-MAY-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Australia, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic non small cell lung cancer, 27-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic non small cell lung cancer" id="3665" name="indication"></Field><Field value="Australia" id="AU" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="27-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic non small cell lung cancer, 21-APR-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic non small cell lung cancer" id="3665" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="21-APR-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, EU, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic non small cell lung cancer, 27-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic non small cell lung cancer" id="3665" name="indication"></Field><Field value="EU" id="EU" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="27-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic non small cell lung cancer, 12-MAY-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic non small cell lung cancer" id="3665" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="12-MAY-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer, 14-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="14-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Israel, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer, 14-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="Israel" id="IL" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="14-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Italy, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer, 14-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="Italy" id="IT" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="14-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer, 14-OCT-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="14-OCT-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2016-11-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 1 Clinical, Japan, [&lt;Link targetType="company" targetId="18681"&gt;Ono Pharmaceutical Co Ltd&lt;/Link&gt;], Solid tumor, 07-NOV-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Ono Pharmaceutical Co Ltd" id="18681" name="company"></Field><Field value="Solid tumor" id="725" name="indication"></Field><Field value="Japan" id="JP" name="country"></Field><Field value="Phase 1 Clinical" id="C1" name="drugPhaseHighest"></Field><Field value="07-NOV-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="REMOVED"><Date>2016-11-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stomach tumor&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stomach tumor" id="127" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2016-11-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Israel, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stomach tumor&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stomach tumor" id="127" name="indication"></Field><Field value="Israel" id="IL" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2016-11-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Italy, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stomach tumor&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stomach tumor" id="127" name="indication"></Field><Field value="Italy" id="IT" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2016-11-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stomach tumor&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stomach tumor" id="127" name="indication"></Field><Field value="US" id="US" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2016-11-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Cancer&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Cancer" id="651" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2016-11-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Japan, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Cancer&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Cancer" id="651" name="indication"></Field><Field value="Japan" id="JP" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2016-11-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Cancer&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Cancer" id="651" name="indication"></Field><Field value="US" id="US" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2016-11-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Japan, [&lt;Link targetType="company" targetId="18681"&gt;Ono Pharmaceutical Co Ltd&lt;/Link&gt;], Cancer&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Ono Pharmaceutical Co Ltd" id="18681" name="company"></Field><Field value="Cancer" id="651" name="indication"></Field><Field value="Japan" id="JP" name="country"></Field></FieldsRemoved></Change><Change type="updated"><Date>2016-11-08T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; By November 2016, Ono had initiated phase I trials in Japan in patients with solid tumors [&lt;ulink linkID="1870308" linkType="Reference"&gt;1870308&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="1870308" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2016-11-08T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; In May 2016, a phase I trial in relapsed or refractory chronic lymphocytic leukemia and lymphomas was expanded to a phase I/II trial in  patients with relapsed or refractory B-cell malignancies testing  BMS-986016 alone or in combination with nivolumab [&lt;ulink linkID="1543968" linkType="Reference"&gt;1543968&lt;/ulink&gt;].&lt;br/&gt; By November 2016, Ono had initiated phase I trials in Japan in solid tumors [&lt;ulink linkID="1870308" linkType="Reference"&gt;1870308&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1543968" type="updated"></SourceLink><SourceLink id="1870308" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2016-11-24T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; In November 2016, an open-label, safety, tolerability, and efficacy  phase I trial (NCT02966548; CA224-034) of the drug   in combination with nivolumab, was to begin in  December 2016 in advanced solid tumor patients (expected n = 27). The study was to complete in July 2020 [&lt;ulink linkID="1877847" linkType="Reference"&gt;1877847&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="1877847" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2016-12-26T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; In December 2016, 	a phase II trial  (NCT02996110; FRACTION-RCC; CA018-005; 2016-003082-26) in patients (n = 650) with advanced renal cell carcinoma was planned for January 2017. The trial was to end in January 2022 [&lt;ulink linkID="1888107" linkType="Reference"&gt;1888107&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="1888107" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2017-01-13T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... therapy included grade 3 mucositis and grade 4 ventricular fibrillation, elevated lipase, and myocarditis. There were no treatment-related deaths. Objective tumor regression was observed with BMS-986016 alone, and with combination therapy in PD-1-naive patients and in patients with disease progression on nivolumab monotherapy [&lt;ulink linkID="1892020" linkType="Reference"&gt;1892020&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="1892020" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2017-01-13T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; in November 2016,  preliminary  data supporting ongoing development were reported [&lt;ulink linkID="1892020" linkType="Reference"&gt;1892020&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1892020" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2017-01-19T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... inflammation, myocarditis and ventricular fibrillation was reported by  13, 6, 2, 1, 3, 2, 1, 2, 1, 0, 0, 0, 1,  2, 2, 2, 0, 1, 0, 0 and 0 patients, respectively, in BMS-986016 treatment group; and 18, 6, 3, 3, 1, 1, 2, 2, 2, 2, 2, 1, 2, 1, 1, 0, 1, 1, 1, 1 and 1 patients, respectively, in BMS-986016 + nivolumab treatment group [&lt;ulink linkID="1884007" linkType="Reference"&gt;1884007&lt;/ulink&gt;].&lt;br/&gt;... diarrhea, hyperthyroidism, influenza-like illness, ligase increased, myalgia, pruritus, rash maculopapular, dehydration, dyspnea, mucosal inflammation, myocarditis and ventricular fibrillation was reported by 16, 6, 1, 2, 1, 2, 2, 0, 0, 1, 1, 2, 0, 0, 0, 0, 0, 0, 0, 0 and 0 patients, respectively, in BMS-986016 treatment group [&lt;ulink linkID="1884007" linkType="Reference"&gt;1884007&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="1884007" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2017-02-13T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Renal cell carcinoma, 07-FEB-17&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Renal cell carcinoma" id="1766" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="07-FEB-17" name="devStatusDate"></Field></FieldsAdded></Change><Change type="updated"><Date>2017-02-13T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; In February 2017, 	a phase II trial   of BMS-986016  in combination with nivolumab in patients  with advanced renal cell carcinoma was initiated in the US [&lt;ulink linkID="1888107" linkType="Reference"&gt;1888107&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1888107" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2017-04-18T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic renal cancer, 17-JAN-17&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic renal cancer" id="3467" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="17-JAN-17" name="devStatusDate"></Field></FieldsAdded></Change><Change type="REMOVED"><Date>2017-04-18T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Renal cell carcinoma&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Renal cell carcinoma" id="1766" name="indication"></Field><Field value="US" id="US" name="country"></Field></FieldsRemoved></Change><Change type="ADDED"><Date>2017-05-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, Europe, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic non small cell lung cancer, 12-MAY-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic non small cell lung cancer" id="3665" name="indication"></Field><Field value="Europe" id="X5" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="12-MAY-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2017-05-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, Australia, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer, 30-NOV-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="Australia" id="AU" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="30-NOV-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2017-05-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, Europe, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer, 30-NOV-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="Europe" id="X5" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="30-NOV-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="REMOVED"><Date>2017-05-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;EU, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic non small cell lung cancer&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic non small cell lung cancer" id="3665" name="indication"></Field><Field value="EU" id="EU" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2017-05-08T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Italy, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="Italy" id="IT" name="country"></Field></FieldsRemoved></Change><Change type="UPDATED"><Date>2017-05-08T00:00:00Z</Date><Reason id="26">Development status: company/indication/territory trio status change</Reason><DetailFormatted>&lt;Detail&gt;Discovery to Phase 2 Clinical, Australia, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic non small cell lung cancer, 12-MAY-16&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic non small cell lung cancer" id="3665" name="indication"></Field><Field value="Australia" id="AU" name="country"></Field><Field newValue="Phase 2 Clinical" newId="C2" oldValue="Discovery" oldId="DR" name="drugPhaseHighest"></Field><Field value="12-MAY-16" name="devStatusDate"></Field></FieldsChanged></Change><Change type="UPDATED"><Date>2017-05-08T00:00:00Z</Date><Reason id="26">Development status: company/indication/territory trio status change</Reason><DetailFormatted>&lt;Detail&gt;Discovery to Phase 2 Clinical, Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic non small cell lung cancer, 12-MAY-16&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic non small cell lung cancer" id="3665" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field><Field newValue="Phase 2 Clinical" newId="C2" oldValue="Discovery" oldId="DR" name="drugPhaseHighest"></Field><Field value="12-MAY-16" name="devStatusDate"></Field></FieldsChanged></Change><Change type="UPDATED"><Date>2017-05-08T00:00:00Z</Date><Reason id="26">Development status: company/indication/territory trio status change</Reason><DetailFormatted>&lt;Detail&gt;Discovery to Phase 2 Clinical, Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer, 30-NOV-16&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field><Field newValue="Phase 2 Clinical" newId="C2" oldValue="Discovery" oldId="DR" name="drugPhaseHighest"></Field><Field value="30-NOV-16" name="devStatusDate"></Field></FieldsChanged></Change><Change type="UPDATED"><Date>2017-05-08T00:00:00Z</Date><Reason id="26">Development status: company/indication/territory trio status change</Reason><DetailFormatted>&lt;Detail&gt;Discovery to Phase 2 Clinical, Israel, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer, 30-NOV-16&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="Israel" id="IL" name="country"></Field><Field newValue="Phase 2 Clinical" newId="C2" oldValue="Discovery" oldId="DR" name="drugPhaseHighest"></Field><Field value="30-NOV-16" name="devStatusDate"></Field></FieldsChanged></Change><Change type="UPDATED"><Date>2017-05-08T00:00:00Z</Date><Reason id="26">Development status: company/indication/territory trio status change</Reason><DetailFormatted>&lt;Detail&gt;Discovery to Phase 2 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic stomach cancer, 30-NOV-16&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic stomach cancer" id="3666" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field newValue="Phase 2 Clinical" newId="C2" oldValue="Discovery" oldId="DR" name="drugPhaseHighest"></Field><Field value="30-NOV-16" name="devStatusDate"></Field></FieldsChanged></Change><Change type="added"><Date>2017-05-19T00:00:00Z</Date><Reason id="13">Other action added</Reason><DetailFormatted>&lt;Detail&gt;Immunostimulant&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Immunostimulant" id="393" name="action"></Field></FieldsAdded></Change><Change type="added"><Date>2017-05-19T00:00:00Z</Date><Reason id="13">Other action added</Reason><DetailFormatted>&lt;Detail&gt;T-lymphocyte stimulator&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="T-lymphocyte stimulator" id="7761" name="action"></Field></FieldsAdded></Change><Change type="updated"><Date>2017-06-15T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsRemoved><SourceLink id="1457655" type="updated"></SourceLink><SourceLink id="1503948" type="updated"></SourceLink><SourceLink id="1543968" type="updated"></SourceLink><SourceLink id="1759748" type="updated"></SourceLink><SourceLink id="1865820" type="updated"></SourceLink><SourceLink id="1870308" type="updated"></SourceLink><SourceLink id="1877847" type="updated"></SourceLink><SourceLink id="1884007" type="updated"></SourceLink><SourceLink id="1888107" type="updated"></SourceLink><SourceLink id="1892020" type="updated"></SourceLink></CitationsRemoved></Change><Change type="updated"><Date>2017-06-15T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsRemoved><SourceLink id="1258009" type="updated"></SourceLink><SourceLink id="1543968" type="updated"></SourceLink><SourceLink id="1759748" type="updated"></SourceLink><SourceLink id="1865820" type="updated"></SourceLink><SourceLink id="1870308" type="updated"></SourceLink><SourceLink id="1888107" type="updated"></SourceLink><SourceLink id="1892020" type="updated"></SourceLink></CitationsRemoved></Change><Change type="updated"><Date>2017-08-14T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; this was ongoing in July 2017 [&lt;ulink linkID="1951672" linkType="Reference"&gt;1951672&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1951672" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2017-08-30T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Melanoma, 26-FEB-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Melanoma" id="205" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="26-FEB-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2017-08-30T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, Europe, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Melanoma, 26-FEB-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Melanoma" id="205" name="indication"></Field><Field value="Europe" id="X5" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="26-FEB-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="added"><Date>2017-08-30T00:00:00Z</Date><Reason id="4">Development profile section added</Reason><DetailFormatted>Regulatory: &lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2017, the FDA granted Orphan designation to a combination of  a fully human mAb specific for LAG3 (presumably BMS-986016) and &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; for treatment of stage IIb to IV melanoma [&lt;ulink linkID="1956217" linkType="Reference"&gt;1956217&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</DetailFormatted><FieldsAdded><Field id="REGULATORY" name="drugDevProfileRegulatory"></Field></FieldsAdded></Change><Change type="updated"><Date>2017-09-05T00:00:00Z</Date><Reason id="3">Drug name changed</Reason><DetailFormatted>&lt;Detail&gt;BMS-986016 to relatlimab&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field newValue="relatlimab" oldValue="BMS-986016" name="drugNameDisplay"></Field></FieldsChanged></Change><Change type="updated"><Date>2017-09-06T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; Bristol-Myers Squibb (BMS) and licensee Ono Pharmaceuticals are developing relatlimab (BMS-986016; ONO-4482), an anti-LAG3 mAb, for the potential intravenous treatment of cancer, including non-small cell lung cancer (NSCLC), hematologic malignancies and gastric cancer [&lt;ulink linkID="1957628" linkType="Reference"&gt;1957628&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1957628" type="updated"></SourceLink></CitationsAdded></Change><Change type="added"><Date>2017-09-29T00:00:00Z</Date><Reason id="15">Technology added</Reason><DetailFormatted>&lt;Detail&gt;Immuno-oncology&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Immuno-oncology" id="1263" name="technology"></Field></FieldsAdded></Change><Change type="updated"><Date>2017-09-29T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... disease control rate  (primary objective) was 49%. Median duration of response  (primary objective) was not reached. In patients with &gt;/= 1 and &lt; 1% LAG-3 expression, ORR was 18 and 5.0%, respectively. Regardless of PD-L1 expression (&gt;/= 1 versus &lt; 1%), ORR was &gt;/= 3.5-fold higher in patients with &gt;/= 1 versus &lt; 1% LAG-3 expression [&lt;ulink linkID="1960559" linkType="Reference"&gt;1960559&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="1960559" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2018-01-18T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 1 Clinical, Japan, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Solid tumor, 07-NOV-16&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Solid tumor" id="725" name="indication"></Field><Field value="Japan" id="JP" name="country"></Field><Field value="Phase 1 Clinical" id="C1" name="drugPhaseHighest"></Field><Field value="07-NOV-16" name="devStatusDate"></Field></FieldsAdded></Change><Change type="updated"><Date>2018-01-18T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; this was ongoing in July 2017 [&lt;ulink linkID="1997926" linkType="Reference"&gt;1997926&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="1997926" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2018-02-12T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, Japan, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Melanoma, 30-JAN-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Melanoma" id="205" name="indication"></Field><Field value="Japan" id="JP" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="30-JAN-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2018-02-12T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, Japan, [&lt;Link targetType="company" targetId="18681"&gt;Ono Pharmaceutical Co Ltd&lt;/Link&gt;], Melanoma, 30-JAN-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Ono Pharmaceutical Co Ltd" id="18681" name="company"></Field><Field value="Melanoma" id="205" name="indication"></Field><Field value="Japan" id="JP" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="30-JAN-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="updated"><Date>2018-02-12T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; By January 2018, phase I/II development was underway in Japan for melanoma [&lt;ulink linkID="2002033" linkType="Reference"&gt;2002033&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="2002033" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2018-03-30T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 20-MAR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="20-MAR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2018-03-30T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Spain, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 20-MAR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Spain" id="ES" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="20-MAR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2018-03-30T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, South America, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 20-MAR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="South America" id="XE" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="20-MAR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="updated"><Date>2018-03-30T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... was planned in the Canada, Spain and Chile, to assess the efficacy of   nivolumab monotherapy versus  nivolumab in combination  with relatlimab in patients (expected n = 700) with previously untreated metastatic or unresectable melanoma. At that time, the trial was planned to begin in April 2018 and complete in March 2022 [&lt;ulink linkID="2017725" linkType="Reference"&gt;2017725&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="2017725" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2018-03-30T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; In  March 2018, a phase II/III trial was planned for metastatic melanoma [&lt;ulink linkID="2017725" linkType="Reference"&gt;2017725&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="2017725" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2018-04-04T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Australia, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 20-MAR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Australia" id="AU" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="20-MAR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2018-04-04T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, New Zealand, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 20-MAR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="New Zealand" id="NZ" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="20-MAR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2018-04-04T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, Europe, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 20-MAR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Europe" id="X5" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="20-MAR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="REMOVED"><Date>2018-04-04T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Spain, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Spain" id="ES" name="country"></Field></FieldsRemoved></Change><Change type="updated"><Date>2018-04-04T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; By January 2018, phase I/II development was underway in Japan for melanoma [&lt;ulink linkID="2002033" linkType="Reference"&gt;2002033&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="2002033" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2018-06-11T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Advanced solid tumor, 08-MAR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Advanced solid tumor" id="3713" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="08-MAR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2018-06-11T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic renal cell carcinoma, 17-JAN-17&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic renal cell carcinoma" id="4250" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="17-JAN-17" name="devStatusDate"></Field></FieldsAdded></Change><Change type="REMOVED"><Date>2018-06-11T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic renal cancer&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic renal cancer" id="3467" name="indication"></Field><Field value="US" id="US" name="country"></Field></FieldsRemoved></Change><Change type="updated"><Date>2018-06-11T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... was planned in June 2018, in the US to assess the safety and anti-tumor activity of relatlimab in combination with both nivolumab and BMS-986205, or in combination with both nivolumab and ipilimumab in patients (expected n =230) with advanced malignant tumors. At that time, the trial was expected to complete in May 2022 [&lt;ulink linkID="2040620" linkType="Reference"&gt;2040620&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="2040620" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2018-06-11T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; Later that month, a phase I/II trial was planned in patients with advanced malignant tumors [&lt;ulink linkID="2040620" linkType="Reference"&gt;2040620&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="2040620" type="updated"></SourceLink></CitationsAdded></Change><Change type="REMOVED"><Date>2018-07-18T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Australia, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Australia" id="AU" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2018-07-18T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2018-07-18T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;New Zealand, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="New Zealand" id="NZ" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2018-07-18T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;Europe, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Europe" id="X5" name="country"></Field></FieldsRemoved></Change><Change type="REMOVED"><Date>2018-07-18T00:00:00Z</Date><Reason id="25">Development status: company/indication/territory trio removed</Reason><DetailFormatted>&lt;Detail&gt;South America, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma&lt;/Detail&gt;</DetailFormatted><FieldsRemoved><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="South America" id="XE" name="country"></Field></FieldsRemoved></Change><Change type="updated"><Date>2018-07-18T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Removed; [&lt;Link targetType="source" targetId="2017725"&gt;2017725&lt;/Link&gt;]&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsRemoved><SourceLink id="2017725" type="updated"></SourceLink></CitationsRemoved></Change><Change type="ADDED"><Date>2018-08-07T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 1 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Metastatic esophageal cancer, 11-JUL-17&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Metastatic esophageal cancer" id="3667" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Phase 1 Clinical" id="C1" name="drugPhaseHighest"></Field><Field value="11-JUL-17" name="devStatusDate"></Field></FieldsAdded></Change><Change type="updated"><Date>2018-08-07T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... Ib/II study (NCT03610711; J1884; IRB00166032) was planned to evaluate the safety of nivolumab or nivolumab in combination with relatlimib after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease). At that time, trial was expected to begin in September 2018 and complete in February 2024 [&lt;ulink linkID="2060473" linkType="Reference"&gt;2060473&lt;/ulink&gt;].&lt;br/&gt; ... the safety of nivolumab or relatlimab 	in the pre-operative setting and nivolumab +/- relatlimab combined with chemoradiation in patients (expected n = 32) with resectable distal esophageal/gastroesophageal junction cancer, in collaboration with Bristol-Myers Squibb. At that time, the trial was expected to complete in February 2022 [&lt;ulink linkID="2060514" linkType="Reference"&gt;2060514&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="2060473" type="updated"></SourceLink><SourceLink id="2060514" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2018-08-07T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; Bristol-Myers Squibb (BMS) and licensee Ono Pharmaceuticals are developing relatlimab (BMS-986016; ONO-4482), an anti-LAG3 mAb, for the potential intravenous treatment of cancer, including non-small cell lung cancer (NSCLC), hematologic malignancies, gastric cancer, metastatic esophageal cancer and metastatic melanoma [&lt;ulink linkID="2060514" linkType="Reference"&gt;2060514&lt;/ulink&gt;].&lt;br/&gt;In July 2017, a phase I trial of relatlimab  plus nivolumab began in advanced gastroesophageal cancer [&lt;ulink linkID="2060514" linkType="Reference"&gt;2060514&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="2060514" type="updated"></SourceLink></CitationsAdded></Change><Change type="ADDED"><Date>2019-01-08T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Discovery, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 31-OCT-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Discovery" id="DR" name="drugPhaseHighest"></Field><Field value="31-OCT-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="updated"><Date>2019-01-08T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... of intravenous nivolumab plus relatlimab and nivolumab plus ipilimumab in patients (expected n = 36) with MHC-II (+) melanoma, in the US. The primary endpoint was to measure the change in activated GZMB+ CD8+T-cell density intratumorally, of two immunotherapy regimens. At that time, the trial was expected to complete in November 2023 [&lt;ulink linkID="2090827" linkType="Reference"&gt;2090827&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="2090827" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2019-01-08T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; In October 2018, a phase II trial was planned for metastatic melanoma in the US [&lt;ulink linkID="2090827" linkType="Reference"&gt;2090827&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="2090827" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2019-02-11T00:00:00Z</Date><Reason id="10">Highest status change</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical to Phase 3 Clinical&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field newValue="Phase 3 Clinical" newId="C3" oldValue="Phase 2 Clinical" oldId="C2" name="drugPhaseHighest"></Field></FieldsChanged></Change><Change type="ADDED"><Date>2019-02-11T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 3 Clinical, Australia, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 10-APR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Australia" id="AU" name="country"></Field><Field value="Phase 3 Clinical" id="C3" name="drugPhaseHighest"></Field><Field value="10-APR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2019-02-11T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 3 Clinical, Canada, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 10-APR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Canada" id="CA" name="country"></Field><Field value="Phase 3 Clinical" id="C3" name="drugPhaseHighest"></Field><Field value="10-APR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2019-02-11T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 3 Clinical, Israel, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 10-APR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Israel" id="IL" name="country"></Field><Field value="Phase 3 Clinical" id="C3" name="drugPhaseHighest"></Field><Field value="10-APR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2019-02-11T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 3 Clinical, Mexico, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 10-APR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Mexico" id="MX" name="country"></Field><Field value="Phase 3 Clinical" id="C3" name="drugPhaseHighest"></Field><Field value="10-APR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2019-02-11T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 3 Clinical, New Zealand, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 10-APR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="New Zealand" id="NZ" name="country"></Field><Field value="Phase 3 Clinical" id="C3" name="drugPhaseHighest"></Field><Field value="10-APR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2019-02-11T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 3 Clinical, Europe, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 10-APR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="Europe" id="X5" name="country"></Field><Field value="Phase 3 Clinical" id="C3" name="drugPhaseHighest"></Field><Field value="10-APR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2019-02-11T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 3 Clinical, South America, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 10-APR-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="South America" id="XE" name="country"></Field><Field value="Phase 3 Clinical" id="C3" name="drugPhaseHighest"></Field><Field value="10-APR-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="UPDATED"><Date>2019-02-11T00:00:00Z</Date><Reason id="26">Development status: company/indication/territory trio status change</Reason><DetailFormatted>&lt;Detail&gt;Discovery to Phase 3 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Stage IV melanoma, 10-APR-18&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Stage IV melanoma" id="3257" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field newValue="Phase 3 Clinical" newId="C3" oldValue="Discovery" oldId="DR" name="drugPhaseHighest"></Field><Field value="10-APR-18" name="devStatusDate"></Field></FieldsChanged></Change><Change type="updated"><Date>2019-02-11T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... the US, Argentina, Australia,  Europe, Canada, Chile, Colombia,  Israel, Mexico and New Zealand to assess relatlimab in combination with nivolumab in patients with advanced melanoma (expected n = 700). The primary endpoint would be progession-free survival up to 5 years. At that time, the trial was expected to complete in March 2022 [&lt;ulink linkID="2117897" linkType="Reference"&gt;2117897&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="2117897" type="updated"></SourceLink></CitationsAdded></Change><Change type="updated"><Date>2019-02-11T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; In April 2018, a phase II/III trial was initiated to assess the drug in combination with nivolumab in advanced melanoma patients [&lt;ulink linkID="2117897" linkType="Reference"&gt;2117897&lt;/ulink&gt;].&lt;br/&gt;Removed; [&lt;Link targetType="source" targetId="1892020"&gt;1892020&lt;/Link&gt;], [&lt;Link targetType="source" targetId="2090827"&gt;2090827&lt;/Link&gt;]&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="2117897" type="updated"></SourceLink></CitationsAdded><CitationsRemoved><SourceLink id="1892020" type="updated"></SourceLink><SourceLink id="2090827" type="updated"></SourceLink></CitationsRemoved></Change><Change type="ADDED"><Date>2019-02-21T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 1 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Glioblastoma, 18-NOV-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Glioblastoma" id="2454" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field value="Phase 1 Clinical" id="C1" name="drugPhaseHighest"></Field><Field value="18-NOV-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="updated"><Date>2019-03-04T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Premarketing: Added; ... no DLTs at highest dose (800 mg) of BMS-986016, while one DLT of grade-3 serum ALT (at end of cycle-2) was reported with anti-CD137 at the top dose (8 mg flat). At end of cycle-2, 3 of 12 patients developed elevated ALT and this was considered possibly related to anti-CD137. Grade 1 elevated ALTs were observed in another two patients [&lt;ulink linkID="2118193" linkType="Reference"&gt;2118193&lt;/ulink&gt;].&lt;br/&gt; ... (expected n = 100). The primary endpoint was MTD of BMS-986016 and BMS-663513 as monotherapies or in combination with nivolumab. At that time, the anti-CD137 antibody (BMS-663513) treatment arm was closed by BMS on 10/16/18 due to closure of BMS urelumab development program and trial was estimated to complete in December 2020 [&lt;ulink linkID="2122424" linkType="Reference"&gt;2122424&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="PREMARKETING" name="drugDevProfilePremarketing"></Field></FieldsChanged><CitationsAdded><SourceLink id="2118193" type="updated"></SourceLink><SourceLink id="2122424" type="updated"></SourceLink></CitationsAdded></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="40">New Clinical Trial Added</Reason><DetailFormatted>&lt;Detail&gt;Radiation Enhanced Assessment of Combination Therapies in Immuno-Oncology - Nivolumab or Nivolumab in Combination With Other Immuno-Oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Radiation Enhanced Assessment of Combination Therapies in Immuno-Oncology - Nivolumab or Nivolumab in Combination With Other Immuno-Oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer" id="348285" name="trialTitle"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2019-04-29T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, Australia, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Advanced solid tumor, 25-MAY-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Advanced solid tumor" id="3713" name="indication"></Field><Field value="Australia" id="AU" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="25-MAY-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="ADDED"><Date>2019-04-29T00:00:00Z</Date><Reason id="24">Development status: company/indication/territory trio added</Reason><DetailFormatted>&lt;Detail&gt;Phase 2 Clinical, Europe, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Advanced solid tumor, 25-MAY-18&lt;/Detail&gt;</DetailFormatted><FieldsAdded><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Advanced solid tumor" id="3713" name="indication"></Field><Field value="Europe" id="X5" name="country"></Field><Field value="Phase 2 Clinical" id="C2" name="drugPhaseHighest"></Field><Field value="25-MAY-18" name="devStatusDate"></Field></FieldsAdded></Change><Change type="UPDATED"><Date>2019-04-29T00:00:00Z</Date><Reason id="26">Development status: company/indication/territory trio status change</Reason><DetailFormatted>&lt;Detail&gt;Discovery to Phase 2 Clinical, US, [&lt;Link targetType="company" targetId="15065"&gt;Bristol-Myers Squibb Co&lt;/Link&gt;], Advanced solid tumor, 25-MAY-18&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field value="Bristol-Myers Squibb Co" id="15065" name="company"></Field><Field value="Advanced solid tumor" id="3713" name="indication"></Field><Field value="US" id="US" name="country"></Field><Field newValue="Phase 2 Clinical" newId="C2" oldValue="Discovery" oldId="DR" name="drugPhaseHighest"></Field><Field value="25-MAY-18" name="devStatusDate"></Field></FieldsChanged></Change><Change type="updated"><Date>2019-05-20T00:00:00Z</Date><Reason id="5">Development profile section source updates</Reason><DetailFormatted>&lt;Detail&gt;Summary: Added; in February 2019, phase III development of  relatlimab plus nivolumab in first-line treatment of melanoma was underway [&lt;ulink linkID="2123173" linkType="Reference"&gt;2123173&lt;/ulink&gt;].&lt;br/&gt;&lt;/Detail&gt;</DetailFormatted><FieldsChanged><Field id="SUMMARY" name="drugDevProfileSummary"></Field></FieldsChanged><CitationsAdded><SourceLink id="2123173" type="updated"></SourceLink></CitationsAdded></Change></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugChangeHistoryOutput>